Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 14/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 13/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13314799 | 0.85 | BCAT1 (0.42) | BCAT1BCAT2 | |
| SCHEMBL9877348 | 0.84 | BCAT1 (0.50) | BCAT1BCAT2 | |
| SCHEMBL26563103 | 0.84 | BCAT1 (0.42) | BCAT1BCAT2 | |
| Saflufenacil SCHEMBL712168 | 0.82 | SCN9A (0.39) | SCN9A | |
| Saflufenacil SCHEMBL29349941 | 0.82 | SCN9A (0.39) | SCN9A | |
| SCHEMBL6049375 | 0.81 | SCN9A (0.38) | SCN9A | |
| SCHEMBL9423008 | 0.79 | BCAT1 (0.53) | BCAT1BCAT2 | |
| SCHEMBL25046408 | 0.79 | SCN9A (0.39) | SCN9A | |
| SCHEMBL25047106 | 0.79 | BCAT1 (0.46) | BCAT1BCAT2 | |
| SCHEMBL9964547 | 0.79 | SCN9A (0.39) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146030-A1 | POST-TREATMENT METHOD FOR SAFLUFENACIL-CONTAINING REACTION SOLUTION | SHANDONG WEIFANG RAINBOW CHEMICAL CO.,LTD (CN) | 2026-05-28 | — | — | US | claimed |
| CN-119735556-A | Post-treatment method of saflufenacil reaction liquid | 山东潍坊润丰化工股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| US-20260146030-A1 | POST-TREATMENT METHOD FOR SAFLUFENACIL-CONTAINING REACTION SOLUTION | SHANDONG WEIFANG RAINBOW CHEMICAL CO.,LTD (CN) | 2026-05-28 | — | — | US | disclosed |
| EP-4313954-B1 | PREPARATION OF 2-CHLORO-4-FLUORO-5-NITROBENZOIC ACID | ADAMA AGAN LTD (IL) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025124321-A1 | PREPARATION METHOD FOR URACIL COMPOUND AND USE OF URACIL COMPOUND | 江苏中旗科技股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| US-20250115560-A1 | A NEW PROCESS OF SAFLUFENACIL PRODUCTION USING NOVEL INTERMEDIATES | ADAMA AGAN LTD (IL) | 2025-04-10 | — | — | US | disclosed |
| CN-119735556-A | Post-treatment method of saflufenacil reaction liquid | 山东潍坊润丰化工股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20240217915-A1 | PREPARATION OF 2-CHLORO-4-FLUORO-5-NITROBENZOIC ACID | ADAMA AGAN LTD. (IL) | 2024-07-04 | — | — | US | disclosed |
| US-20240174620-A1 | SOLID FORMS OF SAFLUFENACIL-SODIUM AND SAFLUFENACIL-POTASSIUM, PROCESS OF PREPARATION AND USE THEREOF | ADAMA AGAN LTD. (IL) | 2024-05-30 | — | — | US | disclosed |
| CN-117794897-A | Novel process for producing pyribenzoxim using novel intermediates | 安道麦阿甘有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4313954-A1 | PREPARATION OF 2-CHLORO-4-FLUORO-5-NITROBENZOIC ACID | Adama Agan Ltd. (IL) | 2024-02-07 | — | — | EP | disclosed |
| US-20080033174-A1 | Method for the Production of 3-Phenyl (Thio) Uracils and Dithiouracils | BASF AKTIENGESELLSCHAFT (DE) | 2008-02-07 | — | — | US | disclosed |
| EP-1692115-B1 | METHOD FOR PRODUCING 3-PHENYL(THIO)URACILS AND 3-PHENYLDITHIOURACILS | BASF AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1692115-B1 | METHOD FOR PRODUCING 3-PHENYL(THIO)URACILS AND 3-PHENYLDITHIOURACILS | BASF AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1773787-A1 | METHOD FOR THE PRODUCTION OF 3-PHENYL(THIO)URACILS AND DITHIOURACILS | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-18 | — | — | EP | disclosed |
| US-20060293520-A1 | Mehtod for producing 3-phenyl(thio)uracils and 3-phenyldithiouracils | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | US | disclosed |
| WO-2006125746-A1 | METHOD FOR PRODUCTION OF 1-ALKYL-3-PHENYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-30 | — | — | WO | disclosed |
| EP-1692115-A1 | METHOD FOR PRODUCING 3-PHENYL(THIO)URACILS AND 3-PHENYLDITHIOURACILS | BASF AKTIENGESELLSCHAFT (DE) | 2006-08-23 | — | — | EP | disclosed |
| WO-2006010474-A1 | METHOD FOR THE PRODUCTION OF 3-PHENYL(THIO)URACILS AND DITHIOURACILS | BASF AKTIENGESELLSCHAFT (DE) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005054208-A1 | METHOD FOR PRODUCING 3-PHENYL(THIO)URACILS AND 3-PHENYLDITHIOURACILS | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293520-A1 | Mehtod for producing 3-phenyl(thio)uracils and 3-phenyldithiouracils | HPRT1, TH, METTL3 | BCAT1 776/4885BCAT2 925/4885SCN9A 2711/4885 |
| US-20250115560-A1 | A NEW PROCESS OF SAFLUFENACIL PRODUCTION USING NOVEL INTERMEDIATES | DPYD, PDK1, CYP2S1 | BCAT1 204/4885BCAT2 309/4885SCN9A 2422/4885 |
| US-20240174620-A1 | SOLID FORMS OF SAFLUFENACIL-SODIUM AND SAFLUFENACIL-POTASSIUM, PROCESS OF PREPARATION AND USE THEREOF | KCNK5, SF3B5, KCNJ1 | BCAT1 2439/4885BCAT2 2198/4885SCN9A 312/4885 |
| US-20240217915-A1 | PREPARATION OF 2-CHLORO-4-FLUORO-5-NITROBENZOIC ACID | CYP4F12, COXFA4, NDUFS5 | BCAT1 431/4885BCAT2 346/4885SCN9A 686/4885 |
| US-20080033174-A1 | Method for the Production of 3-Phenyl (Thio) Uracils and Dithiouracils | TPMT, TYMP, TYMS | BCAT1 1054/4885BCAT2 1306/4885SCN9A 4240/4885 |
| US-20260146030-A1 | POST-TREATMENT METHOD FOR SAFLUFENACIL-CONTAINING REACTION SOLUTION | MTAP, TPMT, STAU1 | BCAT1 1541/4885BCAT2 872/4885SCN9A 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.